Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

Twenty patients receiving a variety of emetogenic cytotoxics (including cisplatin in 5) were given a single i.v. infusion of 40 micrograms kg-1 of BRL43694 (as the hydrochloride salt) in successive groups of 3-4 patients between 0-6 hours after chemotherapy. Eleven patients were completely protected...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, J., Raina, V., Lewis, C., Adams, L., Soukop, M., Rapeport, W. G., Zussman, B. D., Rankin, E. M., Kaye, S. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1988
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246838/
https://www.ncbi.nlm.nih.gov/pubmed/2851312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246838/
https://www.ncbi.nlm.nih.gov/pubmed/2851312

Ejemplares similares